scholarly journals Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America

2012 ◽  
Vol 24 (2) ◽  
pp. 249-256 ◽  
Author(s):  
Javier Torres ◽  
Pelayo Correa ◽  
Catterina Ferreccio ◽  
Gustavo Hernandez-Suarez ◽  
Rolando Herrero ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Latin America ◽  
Cancer Incidence ◽  
Mountainous Regions ◽  
Incidence And Mortality

scholarly journals Thyroid cancer incidence and mortality in Latin America

2018 ◽  
Author(s):  
Fábia Cheyenne Gomes de Morais Fernandes ◽  
Dyego Leandro Bezerra de Souza ◽  
Maria Paula Curado ◽  
Isabelle Ribeiro Barbosa
Keyword(s):  
Latin America ◽  
Thyroid Cancer ◽  
Costa Rica ◽  
Cancer Incidence ◽  
World Health ◽  
International Agency ◽  
Mortality Data ◽  
Incidence Trends ◽  
Incidence And Mortality ◽  
Thyroid Cancer Incidence

This study analyzed trends in thyroid cancer incidence and mortality in countries of Latin America. Ecological study of time series, with incidence data extracted from the International Agency for Research on Cancer (IARC), in the 1990-2012 period and mortality data obtained from 16 countries of the World Health Organization (WHO), in the 1995-2013 period. The trend of incidence rate was analyzed by the Joinpoint regression. The average annual percentage change (AAPC) and the 95% confidence interval (CI 95%) were calculated for incidence and mortality. The average rate of thyroid cancer incidence was higher in Quito (Ecuador) between the ages of 40 to 59 years old, 42.2 new cases per 100,000 inhabitants, as well as mortality 4.8 deaths per 100,000 women inhabitants above 60 years old. There was an increase in thyroid cancer incidence trends in women, for all age groups, in Cali, Costa Rica and Quito and men in Costa Rica; there was stability above the age of 60 years old in Cali, Goiania, Quito and Valdivia in men, as well as women in Goiania and Valdivia. There was a trend of increasing mortality for females in three countries: Ecuador (AAPC= 3,28 CI 95% 1,36;5,24), Guatemala (AAPC= 6,14 CI 95% 2,81;9,58) and Mexico (AAPC= 0,67 CI 95% 0,16;1,18). Thyroid cancer in Latin America showed a high incidence, with increased incidence in women. Stability in mortality was observed for most countries of Latin America.

scholarly journals Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands

Gut ◽  
2020 ◽  
pp. gutjnl-2020-322200 ◽  
Author(s):  
Tsung-Hsien Chiang ◽  
Wei-Jung Chang ◽  
Sam Li-Sheng Chen ◽  
Amy Ming-Fang Yen ◽  
Jean Ching-Yuan Fann ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Cancer Incidence ◽  
Control Period ◽  
Eradication Therapy ◽  
Incidence Rates ◽  
Long Term Effects ◽  
Incidence And Mortality ◽  
H Pylori

ObjectiveAlthough mass eradication of Helicobacter pylori has been proposed as a means to eliminate gastric cancer, its long-term effects remain unclear.DesignMass eradication of H. pylori infection was launched in 2004 and continued until 2018 for a high-risk Taiwanese population aged 30 years or older dwelling on Matsu Islands with prevalent H. pylori infection. Test positives for the 13C-urea breath test underwent eradication therapy. We evaluated the effectiveness of the mass eradication in reducing two main outcomes, incidence and mortality rates of gastric cancer, until the end of 2016 and 2018, respectively.ResultsAfter six rounds of mass screening and eradication, the coverage rate reached 85.5% (6512/7616). The referral rate for treatment was 93.5% (4286/4584). The prevalence rates of H. pylori fell from 64.2% to 15.0% with reinfection rates of less than 1% per person-year. The presence and severity of atrophic gastritis and intestinal metaplasia also decreased with time. Compared with the historical control period from 1995 to 2003, the effectiveness in reducing gastric cancer incidence and mortality during the chemoprevention period was 53% (95% CI 30% to 69%, p<0.001) and 25% (95% CI −14% to 51%, p=0.18), respectively. No significant changes were noted in the incidence rates of other digestive tract cancers or the antibiotic resistance rate of H. pylori.ConclusionPopulation-based eradication of H. pylori has significantly reduced gastric cancer incidence with no increase in the likelihood of adverse consequences. A significant reduction in mortality is likely to be achieved with a longer follow-up period.Trial registration numberNCT00155389

scholarly journals Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality

2012 ◽  
Vol 104 (6) ◽  
pp. 488-492 ◽  
Author(s):  
Jun-Ling Ma ◽  
Lian Zhang ◽  
Linda M. Brown ◽  
Ji-You Li ◽  
Lin Shen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Cancer Incidence ◽  
Incidence And Mortality

scholarly journals Esophageal and gastric cancer incidence and mortality in alendronate users

2012 ◽  
Vol 27 (3) ◽  
pp. 679-686 ◽  
Author(s):  
Bo Abrahamsen ◽  
Michael Pazianas ◽  
Pia Eiken ◽  
R Graham G Russell ◽  
Richard Eastell
Keyword(s):  
Gastric Cancer ◽  
Cancer Incidence ◽  
Incidence And Mortality

scholarly journals Analysis of the National Cancer Institute’s Investment in Site-Specific Cancer Research Funding Involving Collaborators in Latin America and Its Correspondence to Regional Cancer Burden

2020 ◽  
Vol 6 (Supplement_1) ◽  
pp. 21-21
Author(s):  
Jasmin Serena Vargas ◽  
Rachel Abudu ◽  
Kalina Duncan
Keyword(s):  
Cancer Research ◽  
Latin America ◽  
Cancer Incidence ◽  
National Cancer Institute ◽  
Research Funding ◽  
Tumor Site ◽  
Site Specific ◽  
Cancer Burden ◽  
Incidence And Mortality ◽  
Uterine Cancers

PURPOSE Economic and social-behavioral changes over the last two decades in Latin America and the Caribbean (LAC) are associated with increases in the regional cancer burden. We aim to describe the National Cancer Institute–funded extramural research portfolio with collaborators in the LAC between fiscal years 2014 and 2018 and compare project numbers by site with subregional cancer burden. METHODS This analysis included National Cancer Institute–funded extramural projects with LAC collaborators from fiscal years 2014 to 2018 from the National Institutes of Health IMPAC II database. Projects were stratified by Pan American Health Organization’s Latin American subregions, tumor sites, and regional site-specific rates of cancer incidence and mortality using Globocan 2018 estimates. To better understand subregional variations in cancer incidence and mortality, this analysis focused on the top 5 sites of incidence and mortality in LAC after breast and prostate cancer. RESULTS Between fiscal years 2014 and 2018, 108 projects with LAC collaborators were funded. Project collaborators came from 22 countries in the region, and projects covered 20 tumor sites. The Southern Cone had the most projects funded, followed by the Central American Isthmus and Mexico, Andes, Latin Caribbean, and non-Latin Caribbean—this was roughly proportional to subregional populations. Variation exists at the subregional level for the top 5 cancers when comparing incidence and mortality with subregional project counts. Disparities between projects and incidence by tumor site were the largest for colorectal, lung, and uterine cancers. Disparities between projects and mortality by tumor site were the largest for lung and uterine cancers. Disparities between projects and both components of cancer burden by subregion were the largest for the Latin Caribbean and non-Latin Caribbean. The number of funded projects for Kaposi sarcoma and non-Hodgkin lymphoma largely outpaced both incidence and mortality in every subregion. CONCLUSION This analysis suggests that projects’ alignment with cancer burden is variable by subregion, provides an understanding of cancer research funding by site, and highlights areas of interest for additional investigation, training, and collaboration in LAC.

Sign in / Sign up

Export Citation Format

Share Document